We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sun Pharmaceutical announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYA™ (tildrakizumab-asmn) in patients with active psoriatic arthritis. The interim analysis revealed that over 71 percent of patients treated with ...